Background {#Sec1}
==========

Primary hepatocellular carcinoma (HCC) accounts for 90% of primary liver cancer in China \[[@CR1]\]. The presence of inferior vena cava tumor thrombosis (IVCTT) in patients with HCC is considered critically closely associated with poor prognosis \[[@CR2]--[@CR6]\]. The staging system issues by the Barcelona Clinic Liver Cancer (BCLC) / American Association for the Study of Liver Diseases (AASLD) recommends the palliative care for patients in whom unsatisfactory survival is predicted \[[@CR7]\]. With the advances in surgical techniques and increases in the quality of perioperative care, surgical resection is associated with acceptable prognosis in HCC patients with IVCTT, especially patients who undergo R0 resection \[[@CR8]--[@CR10]\].

Herein, we report an HCC patient with IVCTT who underwent hepatectomy combined with IVC thrombectomy via the anterior approach and we summarized the treatments and outcomes of previous published studies that covered similar patients.

Case presentation {#Sec2}
=================

A 49-year-old male Chinese HCC patient with chronic hepatitis B virus (HBV) infection (having lasted more than 20 years) and cirrhosis. The laboratory results showed the following: alanine aminotransferase (ALT) 43.4 U/L, aspartate aminotransferase (AST) 35.7 U/L, alkaline phosphatase (ALP) 200.5 U/L, gamma-glutamyl transpeptidase (GGT) 188.1 U/L, bilirubin (TBil) 15.5 μmol/L, and a-fetoprotein (AFP) \> 2000 μg/L. Liver function of the patient was Child-Pugh A grade and preoperative indocyanine green retention rate (ICG) was 10.5%.

Computed tomography (CT) showed a large mass about 11.3 × 9.9 cm^2^ in size in the right hepatic lobe, and a tumor thrombus (TT) in the right hepatic vein (RHV) extending into the IVC (Fig. [1](#Fig1){ref-type="fig"}a and b). Fig. 1**a** CT scan showing a huge HCC located in the right hepatic lobe with tumor thrombus (arrow) entering the IVC. **b** Coronal CT suggests IVTT had passed the diaphragm level, but had not enter the right atrium (arrow). **c** Anterior approach right hepatectomy combined with IVCTT thrombectomy

Using both his medical history and imaging findings, he was diagnosed with HCC associated with IVCTT. The clinical stage was BCLC stage C. The patient had no symptoms of right heart failure or pulmonary embolization at admission. Considering that the patient had normal hepatic function without distant metastasis, anterior approach right hepatectomy combined with IVC thrombectomy using trans-diaphragmatic intrapericardial IVC occlusion was planned for this patient (Fig. [1](#Fig1){ref-type="fig"}c).

Surgery was performed via a subcostal inverse-L-shaped incision. At laparotomy, a tumor located in the right lobe of cirrhotic liver and no detectable ascites or peritoneal metastasis was observed. After the right hepatic artery and the right portal vein branch were ligated, hepatic parenchymal resection was performed using the clamp-crushing technique with inflow occlusion (Pringle's maneuver) following the demarcation (Fig. [2](#Fig2){ref-type="fig"}a). Then the suprarenal IVC and portal vein were dissected and taped from the caudate lobe (Fig. [2](#Fig2){ref-type="fig"}b). The retrohepatic IVC below the confluence of the common channel of the left and middle hepatic veins was encircled by a vascular clamp. The diaphragm was transected via a vertical incision exposing the right atrial appendage. Then intraoperative ultrasonography was used to show that a TT in the RHV, involving the IVC, but it had not entered in the right atrium. The supradiaphragmatic IVC was encircled though trans-diaphragmatic intrapericardial IVC (Fig. [2](#Fig2){ref-type="fig"}c). The sequence of total hepatic vascular exclusion is shown in Fig. [2](#Fig2){ref-type="fig"}d and the IVTT was then removed en bloc successfully with Babcock forceps, the whole removal of IVCTT with IVC exclusion cost 20 min. The total operation required 481 min and the intraoperative hemorrhage was 900 ml. Fig. 2**a** Ligation of the right hepatic artery and portal vein. **b** The suprarenal IVC and portal vein were dissected and encircled (arrow). **c** The supradiaphragmatic IVC was encircled through a vertical incision of the diaphragm (arrow). **d** The sequence of total hepatic vascular exclusion: ① Suprarenal IVC ② The portal vein ③ Supradiaphragmatic IVC ④ Retrohepatic IVC

The macroscopic findings of tumor measured 10 × 11 × 13 cm^3^ and the TT measured 3.0 × 2.0 cm2 (Fig. [3](#Fig3){ref-type="fig"}a). Postoperative histological diagnosis showed moderately differentiated HCC (grade II-III Edmondson) had invaded the right hepatic vein with hepatic fibrosis and intravascular tumor thrombus. No positive resection margins or local lymph node metastasis were observed microscopically (Fig. [3](#Fig3){ref-type="fig"}b). The TNM stage was T3bN0M0. Fig. 3**a** The resected tumor specimens. **b** Hepatocellular carcinoma, II-III, giant size, size 10 × 11 × 13 cm, visible intravascular tumor thrombus, incision without tumor residual (HE staining, × 400). **c** CT examinations and laboratory results of AFP showed no signs of recurrence or metastasis 32 months after the surgery

Postoperative recovery was uneventful. The patient was discharged with few adverse events after the operation. The patient was disease-free at 32 months after the initial treatment (Fig. [3](#Fig3){ref-type="fig"}c).

Discussion and conclusions {#Sec3}
==========================

Despite advances in perioperative therapy and multidisciplinary therapy, IVCTT-presenting HCC is still a significant factor for a dismal prognosis of HCC patients \[[@CR3], [@CR11], [@CR12]\]. The median survival time after surgical resection for HCC with IVCTT was significantly better than that without surgical resection or in patients treated with sorafenib (47.4 vs 4/10.7 months) \[[@CR3], [@CR7]\]. Regarding prognosis, we reviewed 33 case reports of HCC with IVCTT (Table [1](#Tab1){ref-type="table"}) and found the mean patient age to be 55.8 ± 15.4 years, and the mean time that elapsed between diagnosis and treatment was 20 ± 22.8 months in the 17 patients who underwent liver resection and TT, the mean time that elapsed between diagnosis and treatment was 9 ± 4.5 months in the 7 patients who underwent resection of TT alone, and the mean time that elapsed between diagnosis and treatment was 10.4 ± 12.3 months in the 12 patients who received other oncology therapy. These data indicated that aggressive radical resection of thrombus combined with hepatectomy or tumor thrombus extraction alone, might yield better survival than other non-surgical treatment. Table 1Reported cases of hepatocellular carcinoma with IVC involvementNoLiteratureAge/SexLocationSizeIVC InvolvementTreatment TechniqueAdditional TreatmentSurvivalOutcome1Tastekin \[[@CR13]\]24/maleRt lobe6 × 6 × 4 cmIII LVResection of liver tumorResection of tumor thrombus18 moDead2Ehrich \[[@CR14]\]62/maleLt lobeNDIII RAResection of tumor thrombusRadiation therapy12 moAlive3Li \[[@CR15]\]66/maleRt lobe12 cmIII RAResection of liver tumor and tumor thrombusNo6 moDead4Oncale \[[@CR16]\]76/maleRt lobe12 × 8 cmIISorafenibNo14 moDead5Miller \[[@CR17]\]30/maleExtensive involvementNDIII RAResection of tumor thrombusRadiation therapy and immunotherapy6 moAlive6Chang \[[@CR4]\]57/maleRAS9.6 × 8.6 cmIII RAThalidomideNo12 moAlive76/maleMHV2 cmIII RATACEThalidomide18 moDead67/femaleSeg5, Seg87 cmIII RAThalidomideNo5 moAlive7Inoue \[[@CR39]\]67/maleSeg2, Seg31.2 cmIII RAResection of liver tumor and tumor thrombusNo27 moAlive8Luo \[[@CR18]\]35/maleLt lobe, RASNDIII RAPercutaneous microwave ablationNo6 moDead9Goto \[[@CR19]\]36/femaleRt lobeNDIII RAResection of tumor thrombusTACE7 moDead10Kawakam \[[@CR20]\]66/femaleExtensive involvementNDIII RASymptomatic treatmentTACE5 moDead11Sun \[[@CR21]\]45/maleLt lobeNDIII RATACENo46 moAlive12Georgen \[[@CR22]\]22/femaleSeg76 cmIII RAResection of liver tumor and tumor thrombusNo30 moDead13Noguchi \[[@CR23]\]66/maleRt lobe2 cmIII RASymptomatic treatmentNo1 moDead14Ohta \[[@CR43]\]60/maleRt lobeNDIII RAResection of liver tumor and tumor thrombusSorafenib10 moAlive15Sengodan \[[@CR24]\]44/maleRt lobe5.6 × 7.6 × 5.5 cmIII RASorafenibAnticoagulation2 moDead16Hayashida \[[@CR25]\]72/maleLt lobeNDIII RAResection of tumor thrombusTACE6 moDead17Sawada \[[@CR26]\]62/maleExtensive involvementNDIII RAGlypican-3-derived peptide vaccinationTACE, sorafenib56 dDead18Shivathirthan \[[@CR40]\]71/maleSeg 7NDIII RAResection of liver tumor and tumor thrombusTACENDND19Miyazawa \[[@CR27]\]55/maleRAS7 cmIII RAResection of liver tumor and tumor thrombusNo12 moAlive20Li \[[@CR28]\]64/maleSeg 6, Seg75.3 × 3.6 cmIII RAResection of liver tumor and tumor thrombusNo6 moDead21Wu \[[@CR42]\]42/maleRAS1.5 cmIII RAResection of liver tumor and tumor thrombusTACE14 moDead22Giuliani \[[@CR29]\]47/maleLt lobeMutipleIII RAExternal beam radiation therapyNo7 moDead23Leo \[[@CR30]\]45/maleLt lobeNDIII RAResection of liver tumor and tumor thrombusNo6 moAlive24Florman \[[@CR3]\]55/maleLt lobe18 × 3 × 7 cmIII RAResection of liver tumor and tumor thrombusNo3 moAlive25Sung \[[@CR31]\]71/maleRt lobeNDIII RAResection of tumor thrombusSorafenib7 moAlive26Ohwada \[[@CR32]\]77/femaleLLS10 cmIII RAResection of liver tumor and tumor thrombusNo3 moAlive27Lin \[[@CR33]\]57/maleRt lobe4.5 cmIII RAResection of liver tumor and tumor thrombusNo3 DDead28Yogita \[[@CR34]\]61/maleLMS3 cmIII RAResection of liver tumor and tumor thrombusNo56 moDead29Masaki \[[@CR35]\]47/maleSeg 83 × 2.5 × 2 cmIII RAResection of tumor thrombusTAE and radiation therapy8 moDead48/maleSeg 7NDIII LPResection of tumor thrombus in the IVC and LPATAE29 DDead30Kashima \[[@CR20]\]66/maleRt lobe10 × 7 cmIII RAResection of liver tumor and tumor thrombusTACE59 moAlive31Fujisaki \[[@CR36]\]38/femaleLLS8 × 8 cmIII RAResection of liver tumor and tumor thrombusNo15 moAlive32Dazai \[[@CR37]\]42/maleRt lobeNDIII RATACENo7 moDead33Kurahashi \[[@CR38]\]81/maleRt lobe11.5 cmIII RAResection of liver tumor and tumor thrombusOncologic treatment72 moAlive*IVC* inferior vena cava, *LLS* left lateral segment, *LMS* left medial segment, *Lt* left, *MHV* middle hepatic vein, *ND* not described, *RA* right atrium, *RAS* right anterior segment, *Rt* right, *Seg* segment, *TACE* transcatheter arterial chemoembolization, *TAE* transcatheter arterial embolization, *LPA* Left pulmonary artery, *LP* left pulmonary, *mo* months, *II* type II (mentioned in Fig. [4](#Fig4){ref-type="fig"}), *III* type III (mentioned in Fig. [4](#Fig4){ref-type="fig"})

A previous clinical study defined the subtypes of IVCTT-presenting HCC into three types based on the anatomic locations of the IVCTT and heart. The TT located within the subdiaphragmatic IVC was defined as the inferior hepatic type (Type I) (Fig. [4](#Fig4){ref-type="fig"}a), and the IVCTT extended above the diaphragm, but it had not infiltrated the RA. It was defined as superior hepatic type (Type II) (Fig. [4](#Fig4){ref-type="fig"}b), for the intracardiac type (Type III). The TT extended over the diaphragm and had entered the RA (Fig. [4](#Fig4){ref-type="fig"}c) \[[@CR12]\]. Fig. 4IVCTT-presenting HCC is classified into three types. **a** The TT located within the subdiaphragmatic IVC; **b** The IVCTT extended above the diaphragm, but it had not infiltrated the RA; and (**c**) The TT extended over the diaphragm and had advanced into the RA

With the advances in surgical techniques, increasing numbers of successful simultaneous resection of HCC with IVC tumor thrombosis have been reported \[[@CR39]\]. Kokudo et al. reported that the 1-year and 3-year survival rates were 81 and 32%, respectively, and the median survival time was 16.7 months \[[@CR8]\]. Wang et al. reported that the 1-year, 3-year, and 5-year survival rates were 68, 22.5, and 13.5% and the median survival time was 19 months \[[@CR10]\]. These data indicated that resection of HCC and IVCTT might result in better survival than other non-surgical therapies.

Cardiopulmonary bypasses (CPB) and total hepatic vascular exclusion (THVE) have been reported in most previous resection cases \[[@CR40]--[@CR43]\]. However, these technologies have reportedly been associated with the risk of massive hemorrhage and severe vascular injury. Although other new technologies, such as venous bypass, total circulatory arrest with exsanguinations, and concomitant hypothermia, can reduce these risks, technical complexity is still the main limitation of these procedures \[[@CR42], [@CR44]\]. The basis of our technique is that the IVCTT undergo no or minimal adhesion to the venous wall on any macroscopic scale. Similar ideas have been mentioned in two previous articles. We have simplified the surgery procedure and difficulty based on the new surgical concepts. It has been suggested that this surgical procedure could be suitable for HCC patients with IVCTT extended above the diaphragm without entering the RA, and it could reduce the risk of bleeding and vascular injury to a considerable intent.

No-touch surgery is difficult to perform given the anatomical characteristics of the liver \[[@CR45]\]. Recent studies have confirmed that tumor cells diffuse more easily through the portal vein or hepatic vein during the conventional hepatectomy than through other veins and resulting in early recurrence \[[@CR46], [@CR47]\]. Recently, some studies have reported that anterior approach hepatectomy, because involves less manipulation of the liver, can reduce the rate of recurrence of postoperative liver cancer, and extend patient survival \[[@CR48]\]. Clinical, randomized controlled studies reported that half-hepatectomy in the anterior approach significantly reduced the risk of blood loss, improved the survival rate, ensured surgical vision, and reduced the perioperative mortality rate \[[@CR49]\].

During this procedure, a process termed the peeling-off technique was performed because tumor thromboses do not adhere to the wall of the IVC. Previous studies have proved that the peeling off technique can improve the surgical outcome of HCC with portal vein tumor thrombus \[[@CR50], [@CR51]\]. We reported the resection for HCC with IVCTT using the peeling off technique and the long-term survival outcomes are comparable to the current case reports. The low incidence of IVC tumor thrombus in HCC should not preclude the development of new surgical approaches because the peeling-off technique is a minimally invasive approach and deserves further investigation.

In this case, because the IVCTT is above the diaphragm but still outside the RA, the intrathoracic IVC is approached by an abdominal incision of the diaphragm, without the need for a median sternotomy or thoracotomy \[[@CR52], [@CR53]\]. This method prevents any need for splitting the sternum and also reduced surgical trauma, keeping the IVC hiatus and preserved the normal anatomical structures, and offered good surgical exposure.

In conclusion, radical resection of both HCC and IVCTT could be a practical surgical option and useful therapeutic modality for achieving long-term survival or HCC patients with IVCTT extending to the IVC, especially for those IVCTT extending over the diaphragm but outside the RA.
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